Compass Pathways (CMPS, Financial), a leading mental health care company focusing on the development of psilocybin therapy, continues to draw attention from analysts. On May 12, 2025, HC Wainwright & Co. reasserted its stance on CMPS, reiterating its 'Buy' rating.
Notably, analyst Patrick Trucchio from HC Wainwright & Co. has maintained the price target for Compass Pathways at $45.00 USD. This price target showcases the analyst's confidence in CMPS's growth prospects and aligns with their previous assessment, as the price target remains unchanged from its prior listing.
The reiterated 'Buy' rating highlights a consistent investor sentiment towards Compass Pathways (CMPS, Financial) and suggests that the company could offer lucrative prospects in the mental health sector. As of the analysis date, CMPS maintains its strong position without any changes in its target price, reflecting a steady outlook among financial analysts.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Compass Pathways PLC (CMPS, Financial) is $17.30 with a high estimate of $45.00 and a low estimate of $11.00. The average target implies an upside of 356.46% from the current price of $3.79. More detailed estimate data can be found on the Compass Pathways PLC (CMPS) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Compass Pathways PLC's (CMPS, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
